Article Text

Management of patients with HBeAg-negative chronic hepatitis B
  1. Nripen Saikia,
  2. Rupjyoti Talukdar,
  3. Subhasish Mazumder,
  4. Sudeep Khanna,
  5. Rakesh Tandon
  1. Department of Gastroenterology, Pushpawati Singhania Research Institute, New Delhi, India
  1. Correspondence to:
 Dr Nripen Saikia
 Department of Gastroenterology, Pushpawati Singhania Research Institute, Sheikh Sarai Phase II, Press Enclave Marg, New Delhi 110017, India; saikia.n{at}


Chronic hepatitis B (CHB) is one of the leading causes of morbidity and mortality worldwide. Although various drugs are available for the treatment of CHB, emergence of the hepatitis B e antigen (HBeAg)-negative mutant variant, specifically in Asia, the Middle East and southern Europe, is creating a new challenge as this variant is less responsive to available treatments. HBeAg-negative CHB rapidly progresses to cirrhosis and its related complications. This review discusses the available literature on the approved and under-trial treatment options and their respective efficacies for HBeAg-negative CHB.

  • ALT, alanine aminotransferase
  • CHB, chronic hepatitis B
  • ETR, end-of-treatment response
  • HBeAg, hepatitis B e antigen
  • HBsAg, hepatitis B surface antigen
  • HBV, hepatitis B virus
  • HCC, hepatocellular carcinoma
  • IFN, interferon
  • PCR, polymerase chain reaction
  • PEG-IFN, polyethylene glycol moiety attached to interferon
  • YMDD, tyrosine methionine d-aspartate d-aspartate
  • chronic hepatitis B
  • HbeAg negative
  • resistant
  • entecavir
  • lamivudine
  • combination therapy

Statistics from


  • Competing interests: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.